TNFRSF9 and cancer: CD137, also known as 4-1BB, is an inducible co-signaling receptor of the TNF receptor superfamily that has been extensively tested as an immunotherapy target in cancer (66–68), but clinical trials with agonistic anti-CD137 antibodies revealed severe dose-dependent hepatotoxicity (69).